Investment Thesis
Revium Rx exhibits critical financial distress with no revenue generation, mounting annual losses of $13.4M against only $8.3M in total assets, implying approximately 1.5 months of cash runway at current burn rates. The company is destroying shareholder value (ROE: -195.5%, ROA: -162.1%) with zero identifiable business traction, and lacks meaningful insider support despite precarious financial position.
Strengths
- Minimal debt burden (Debt/Equity: 0.0x) provides structural flexibility
- Short-term liquidity adequate with Current Ratio of 2.26x
- Operates in high-potential pharmaceutical sector with significant upside if pipeline succeeds
Risks
- Existential liquidity risk: $1.7M cash against $13.4M annual burn rate equals ~1.5 months runway
- Pre-revenue company with no demonstrated business model or market validation
- Zero insider Form 4 filings suggest lack of management confidence in survival prospects
- Negative returns destroying shareholder value at unsustainable rate (ROE: -195.5%)
- Missing critical operational metrics (cash flow, margins) prevents validation of any turnaround thesis
- OTC listing status indicates heightened regulatory and reporting risk
Key Metrics to Watch
- Monthly cash burn rate and cash balance (survival metric)
- Revenue recognition from any FDA approval or commercial milestone
- Capital raise announcements and dilution magnitude
- Clinical development progress and regulatory submissions
- Insider transactions (confidence indicator)
Financial Metrics
Revenue
N/A
Net Income
-13.4M
EPS (Diluted)
$-0.22
Free Cash Flow
N/A
Total Assets
8.3M
Cash
1.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-195.5%
ROA
-162.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.26x
Quick Ratio
2.26x
Debt/Equity
0.00x
Debt/Assets
17.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T05:15:23.804521 |
Data as of: 2025-12-31 |
Powered by Claude AI